Registry of Lobbyists

Registration - In-house Corporation

sanofi-aventis Canada Inc. / Stephanie Veyrun-Manetti, President and Chief Executive Officer (CEO)

Registration Information

In-house Corporation name: sanofi-aventis Canada Inc.
Previous in-house corporation names
Responsible Officer Name: Stephanie Veyrun-Manetti, President and Chief Executive Officer (CEO) 
Responsible Officer Change History
Initial registration start date: 2005-08-22
Registration status: Active
Registration Number: 951483-5180

Associated Communications

Total Number of Communication Reports: 121

Monthly communication reports in the last 6 months: 0

Version 2 of 40 (2006-02-24 to 2006-08-14)

Version 2 of 40 (2006-02-24 to 2006-08-14) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: sanofi-aventis Canada Inc.
2150, blvd. St-Elzéar o.
Laval, QC  H7L 4A8
Canada
Telephone number: 514-956-6246
Fax number: 514-339-5149  
Responsible officer name and position during the period of this registration: Jérôme Silvestre, Président  
Description of activities: Compagnie de recherche pharmaceutique (Manufacture et ventes)
 
Parent: The corporation is not a subsidiary of any other parent corporations.
Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: Myrtho-Emmanuelle Drouin
Position title: Manager, Public Stakeholder Relations
Public offices held: Yes
 
Name: Michel Giroux
Position title: Executive Director, Patient Access and Government Relations
Public offices held: No
 
Name: Michel G. Tremblay
Position title: Manager, National Stakeholder & Federal Government Relations
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Aboriginal Affairs and Northern Development Canada, Atlantic Canada Opportunities Agency (ACOA), Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Justice Canada (JC), Members of the House of Commons, National Defence (DND), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Privy Council Office (PCO), Public Works and Government Services Canada, Veterans Affairs Canada (VAC), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Aboriginal Affairs, Health, Industry, Intellectual Property, Internal Trade, International Relations, International Trade, Justice and Law Enforcement, Regional Development, Science and Technology
 
Subject Matter: Retrospective: Rencontres )one-on-one) avec les ParlementairesRencontres avec les BureaucratesCommunications écrites
Subject Matter: Prospective: Rencontres (one-on-one) avec les ParlementairesRencontres avec les BureaucratesCommunications écrites
 

Details Regarding the Identified Subject Matter

Categories Description
Legislative Proposal - Cross-border trade (projet de loi proposé)- Stratégie nationale pharmaceutique (politique proposée)-Toutes propositions pouvant affecter notre environnement industriel ou affectant l'accès au marché de nos médicaments
Regulation - Propriété intellectuelle (Linkage Regulations, Data Protection)




Date Modified: